NYSE: DD · Industrial Conglomerates
DuPont
DuPont is a specialty products company with two segments. Healthcare & Water Technologies supplies healthcare products such as medical packaging, plus water technologies. Diversified Industrials covers industrial and building technologies. On November 1, 2025, DuPont spun off its electronics business as Qnity Electronics. In April 2026 it sold the Aramids business (Kevlar, Nomex) to Arclin. 2025 net sales from continuing operations were $6.85 billion; the company posted a net loss of $779 million because of discontinued operations. In June 2026 DuPont carried out a 1-for-3 reverse stock split. PFAS liabilities are shared with Chemours and Corteva under a 2021 agreement (MOU).
Last updated
Analysis last edited: November 6, 2026 · Financial data fetched: October 17, 2026 10:21 (SEC EDGAR) · Source 10-K filed: February 17, 2026
Built on10-K FY2025 · filed 2026-02-1710-Q (quarter ended 2026-09-30) · filed 2026-11-03
Next update expectedAfter FY2026’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.
01
At a glanceFrom SEC data
Eight headline measures, each placed among the companies covered on this site.
- Revenue growthCAGRSmooths out year-to-year swings into "grew X% a year on average." Makes growth pace comparable across companies of very different sizes.
- -19.6%
- Operating marginOperating marginHow many cents of operating profit are left per dollar of revenue. Reflects pricing power and cost structure.
- —
- ROIC minus WACCROIC − WACC spreadThe difference between ROIC and WACC. Consistently positive implies value creation; consistently negative implies value destruction.
- —
- Net debt ÷ EBITDAEBITDAOperating income with D&A added back. A rough proxy for cash-generating power that’s less distorted by capital intensity, depreciation method, or financing/tax differences than net income.
- —
- Cash conversionOperating CF ÷ net income (cash conversion)How much of reported profit shows up as actual cash. 1x or higher means profit is backed by cash.
- —
- Dividend raisesDividend per shareTotal annual dividend paid per share (sum of all declared payments for the year).
- 0 of 5
- P/E todayP/EShare price ÷ EPS — how many years of current earnings the stock price represents. This site uses the period-end figure as reported in the filing.
- 69.6x
- Betaβ (beta)How much a stock moves, on average, for a 1% move in the overall market. Above 1 means more volatile than the market, which raises the return shareholders require. This site computes it from about 2.5 years (roughly 130 weeks) of weekly returns, built from Yahoo Finance daily prices, regressed against an S&P 500 ETF (SPY) as the market proxy, then applies the well-known long-run mean-reversion adjustment (0.67 × β + 0.33) as the WACC default.
- 1.06
Higher than 0% of 372 non-financial companies
Average yearly growth over the years shown
Latest fiscal year (FY2025)
Return on capital above (or below) its estimated cost
Below 0 means more cash than debt
Operating cash flow ÷ net income
Years the dividend per share rose, of the last 5
Latest close 2026-11-04; trailing 12 months to 2026-09-30
Above 1 = moves more than the market
Each marker shows where this company sits among the non-financial companies covered on this site, not all listed companies (left = lowest, right = highest). A high position is not automatically good — for net debt ÷ EBITDA, higher means more debt. Details and formulas are in the sections below and in How to read this.
02
Valuation todayFrom SEC data
Price-based measures at the latest close, next to the same measures at the last fiscal year-end.
Share price$153.58close on 2026-11-04
Market cap$20.95B
- P/EP/EShare price ÷ EPS — how many years of current earnings the stock price represents. This site uses the period-end figure as reported in the filing. today
- 69.6x
- P/BP/BShare price ÷ book value per share. Below 1x means the market values the company below its accounting net worth. This site uses the closing price nearest the fiscal year-end and highlights sub-1x readings. today
- 1.5x
- EV/EBITDAEV/EBITDAEnterprise value (≈ market cap + interest-bearing debt − cash) as a multiple of EBITDA — roughly, "how many years of EBITDA to buy the whole company." Lower is generally viewed as cheaper, and it’s more comparable than P/E across companies with different debt loads or depreciation policies. This site excludes noncontrolling interests from the EV calculation. today
- —
- FCF yieldFree cash flow (FCF)Operating CF minus capital expenditures — cash generated by the business after funding its own investment, available for dividends, buybacks, acquisitions, or debt paydown. Acquisitions and securities purchases (also in investing CF) are not subtracted, so FCF can be positive in a year when total investing CF exceeds operating CF. today
- 1.1%
- Dividend yieldDividend per shareTotal annual dividend paid per share (sum of all declared payments for the year). today
- 2.8%
At FY2025 year-end: —
Earnings: trailing 12 months to 2026-09-30
At FY2025 year-end: 1.2x
Book value at FY2025 year-end
At FY2025 year-end: —
EBITDA for FY2025
At FY2025 year-end: 1.4%
Free cash flow for FY2025
Dividends per share for FY2025
“Today” uses the latest closing price (2026-11-04, Yahoo Finance daily closing prices) and shares outstanding at the last fiscal year-end. The rest of this page — including the financial table and ROIC vs. WACC — uses fiscal year-end prices. These are reference figures, not a judgment of whether the stock is cheap or expensive.
03
What changed since last earningsFrom SEC data
The latest reported quarter against the same quarter a year earlier, the balance sheet against the previous quarter-end, and what management said in its latest earnings release.
Quarter ended Sep 30, 2026.
- Revenue$1.8B → $1.87B (vs. a year earlier)↑ +4.1%$1.8B → $1.87B (vs. a year earlier)
- Net income−$123M → $123M (vs. a year earlier)↑ $123M−$123M → $123M (vs. a year earlier)
- Cash$1.74B → $1.65B (vs. previous quarter-end)↓ −5.1%$1.74B → $1.65B (vs. previous quarter-end)
Source: Form 10-Q ↗ (SEC XBRL). Long-term debt is the tagged long-term debt figure and leaves out short-term borrowings.
From the earnings release of Nov 3, 2026.
Management outlook ↑ Raised
Raised full-year outlook: organic growth about 4.5%, operating EBITDA about $1.785B. Source sentence
We are again raising our full-year financial outlook and now expect organic growth to be about 4.5%, operating EBITDA to be about $1.785 billion and adjusted EPS to be in the range of $7.47 - $7.52 per share, all at or above the high end of our previously communicated guidance,” said Antonella Franzen, DuPont Chief Financial Officer.
Key changes
Q3 net sales $1.9B, up 4%. Source sentence
Net Sales of $1.9 billion increased 4%; organic sales increased 5% versus year-ago period
Plans to repurchase $250M of shares in Q4. Source sentence
Announces intent to repurchase $250 million of shares in the fourth quarter
Written by AI. A line appears only if its figures and direction match the quoted sentence, which an automatic check confirms. Companies' outlooks are their own and may not be met. Read the release ↗
04
Company profileFrom SEC dataShow
- Legal name
- DuPont de Nemours, Inc.
- Headquarters
- WILMINGTON, DE
- Incorporated in
- Delaware
- Fiscal year end
- 12/31
- Exchange & ticker
- NYSE: DD
- Industry
- Industrial Conglomerates
- CIK
- 1666700
- Website
- https://www.dupont.com/ ↗
Workforce (as of FY2025 year-end)
Employees
15,000
Source: Form 10-K (FY2025) cover page and business description
05
Earnings calendarFrom SEC dataShow
When the company reports each quarter: the quarter-end date, the day results were released, and when the 10-Q or 10-K was filed.
Next report
Q4 FY2026
Quarter end: December 2026. In past years, Q4 results were released 37–42 days after quarter end (Feb 10, 2026; Feb 11, 2025; Feb 6, 2024). No date has been announced in the sources this site uses.
Reporting pattern
- Fiscal year ends around December 31.
- Reports four times a year: three quarterly reports (10-Q) and an annual report (10-K) for Q4.
- Earnings releases came 31–42 days after quarter end over the last 12 quarters.
| Quarter | Quarter ended | Earnings release (8-K) | Report filed (10-Q / 10-K) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | Nov 3, 2026 (+34 days) | Nov 3, 2026 10-Q (+34 days) |
| Q2 FY2026 | Jun 30, 2026 | Aug 4, 2026 (+35 days) | Aug 4, 2026 10-Q (+35 days) |
| Q1 FY2026 | Mar 31, 2026 | May 5, 2026 (+35 days) | May 5, 2026 10-Q (+35 days) |
| Q4 FY2025 | Dec 31, 2025 | Feb 10, 2026 (+41 days) | Feb 17, 2026 10-K (+48 days) |
| Q3 FY2025 | Sep 30, 2025 | Nov 6, 2025 (+37 days) | Nov 6, 2025 10-Q (+37 days) |
| Q2 FY2025 | Jun 30, 2025 | Aug 5, 2025 (+36 days) | Aug 5, 2025 10-Q (+36 days) |
| Q1 FY2025 | Mar 31, 2025 | May 2, 2025 (+32 days) | May 2, 2025 10-Q (+32 days) |
| Q4 FY2024 | Dec 31, 2024 | Feb 11, 2025 (+42 days) | Feb 14, 2025 10-K (+45 days) |
| Q3 FY2024 | Sep 30, 2024 | Nov 5, 2024 (+36 days) | Nov 5, 2024 10-Q (+36 days) |
| Q2 FY2024 | Jun 30, 2024 | Jul 31, 2024 (+31 days) | Jul 31, 2024 10-Q (+31 days) |
| Q1 FY2024 | Mar 31, 2024 | May 1, 2024 (+31 days) | May 1, 2024 10-Q (+31 days) |
| Q4 FY2023 | Dec 31, 2023 | Feb 6, 2024 (+37 days) | Feb 15, 2024 10-K (+46 days) |
Source: SEC EDGAR filing history. Release dates are the dates the earnings release was furnished to the SEC on Form 8-K (Item 2.02), which is normally the day results are announced. For a quarter whose 10-Q or 10-K isn’t filed yet, the date is the latest Item 2.02 8-K since the previous report, which may be a preliminary or other results-related update. Fiscal years are labeled by the calendar year in which they end.
06
Flagship products & servicesSite analysis
Healthcare & Water
Healthcare Technologies
2025 sales $1.76B.
Healthcare & Water
Water Technologies
2025 sales $1.48B.
Diversified Industrials
Industrial and Building Technologies
2025 sales $2.00B and $1.61B.
Line names are from the FY2025 Form 10-K revenue disaggregation.
U.S. and worldwide share of flagship products/services
The filings reviewed give no market share figure for the company's products or services.
Reviewed: Form 10-K (FY2025) · Form 10-Q (quarter ended 2026-06-30)
07
Recent strategic focusSite analysis
Portfolio transformation in 2025–2026.
Qnity spin-off
DuPont distributed all Qnity Electronics shares to stockholders effective November 1, 2025; electronics results are reported as discontinued operations.
Source: 8-K filed 2025-11-03
Aramids sale
Completed April 1, 2026 to Arclin for about $1.2B of pre-tax cash, a $300M note and an equity interest valued at $325M.
Source: Q2 2026 press release
Reverse split
A 1-for-3 reverse stock split took effect June 24, 2026; per-share data here are adjusted.
Source: 8-K filed 2026-06-24
North Carolina PFAS settlement
In September 2026 DuPont, Chemours and Corteva agreed to pay $455M over 15 years to settle claims by North Carolina and local entities.
Source: 8-K filed 2026-09-10
Capex ÷ D&A (FY2025)
0.51x
Below depreciation — investment is being pared back
formulacapital expenditures ÷ depreciation & amortization
e.g.$333M ÷ $647M = 0.51x
termsCapital expenditures (capex) · Depreciation & amortization (D&A)
R&D-to-revenue ratio (FY2025)
2.8%
formularesearch & development expense ÷ revenue × 100
e.g.$193M ÷ $6,849M × 100 = 2.8%
M&A spend (6-year total)
$4.54B
Latest year: $55M
Cash-flow-statement spending on acquisitions, net of cash acquired
Where the money goes, over time
Unit: $M. Capex went from $1.19B in FY2020 to $333M in FY2025
- Capex
- R&D
- M&A spend
formulacapital expenditures ÷ depreciation & amortization
termsCapital expenditures (capex) · Depreciation & amortization (D&A)
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-17
08
Key figures at a glanceFrom SEC data
FY2020–FY2025, 6 years.
Revenue (FY2025)
$6.85B
As reported in the 10-K
Revenue CAGR (5 years)
-19.6%▼caution
formula(last-period revenue ÷ first-period revenue) ^ (1 ÷ years) − 1
e.g.($6,849M ÷ $20,397M) ^ (1÷5) − 1 = -19.6%
termsCAGR · ^ (exponent) · Revenue (net sales)
Operating margin (FY2025)
—
formulaoperating income ÷ revenue × 100
ROE (FY2025)
-4.2%▼caution
6-year average: 5.8%
As reported in the 10-K
P/B (FY2025 end)
1.18x
formulafiscal year-end closing price ÷ book value per share
e.g.$120.60 ÷ $102.05 = 1.18x
Period-end (fiscal year-end) value, not today's P/B
EV/EBITDA (FY2025 end)
—
formula(market cap + interest-bearing debt − cash and equivalents) ÷ (operating income + depreciation & amortization)
termsEV/EBITDA · Market capitalization · Interest-bearing debt · EBITDA · Depreciation & amortization (D&A)
Period-end (fiscal year-end) value, not today's multiple
- ▼
Revenue grew -19.6% a year over 5 years (a shrinking trend)
From $20.4B in FY2020 to $6.85B in FY2025. The annualized rate (CAGR) makes it possible to compare growth pace across companies of different sizes.
- ▲
Equity ratio is 64.5% (a high level of financial stability)
The share of total assets funded by equity rather than debt. 50%+ is often read as low bankruptcy risk, though the right level varies by industry (real estate and leasing run lower, for instance).
- ―
Free cash flow was positive in 5 of 6 years
Operating cash flow minus capital expenditures: the cash left over after funding the business’s own investment, available for dividends, buybacks, acquisitions, or debt paydown. A negative year can mean heavy investment, or weak core earnings — worth distinguishing.
- ―
ROE averaged 5.8% over 6 years (latest: -4.2%)
How much profit was generated on shareholders’ equity. Roughly 10%+ is often cited as solid for a U.S. company, though this varies a lot by industry and capital intensity.
09
Business modelSite analysis
Business Model Canvas
The whole company in nine blocks. Left side: how it delivers (partners, activities, resources, costs). Right side: who it serves and how it earns. Every entry comes from the company’s filings shown on this page.
08 · who helps
Key partners
- Chemours and Corteva
07 · what it does
Key activities
Healthcare & Water Technologies
Manufacturing and technical supportDiversified Industrials
Manufacturing
06 · what it draws on
Key resources
Healthcare & Water Technologies
Specialty materials and process technologyDiversified Industrials
Polymers and specialty materials
02 · why customers buy
Value propositions
- Differentiated technology, application expertise and a commitment to quality and performance in healthcare, water and industrial materials.
04 · how it keeps them
Customer relationships
- Engineered components and systems supplied for OEM and operational applications.
03 · how it reaches them
Channels
- Primarily its own sales organization, partnering with distributors, independent retailers, cooperatives and agents for some product lines.
01 · who it serves
Customer segments
Healthcare & Water Technologies
Medical device makers, water treatmentDiversified Industrials
Industrial and construction markets
09 · where money goes
Cost structure
FY2025, share of revenue ($6.85B)
- Cost of revenue65.5%
- Research & development2.8%
- Selling, general & administrative14.9%
Depreciation & amortization (inside the costs above): $647M. Capital spending: $333M.
Source: Form 10-K income statement and cash-flow statement (SEC XBRL).
05 · how money comes in
Revenue streams
Healthcare & Water Technologies
Product salesDiversified Industrials
Product sales
Value propositions, channels and customer relationships: Form 10-K (FY2025)
Healthcare & Water Technologies
Healthcare technologies (including medical packaging solutions) and water technologies.
01 what it draws on
Inputs & resources
- Specialty materials and process technology
02 what it does
Activities
- Manufacturing and technical support
03 who it serves
Customers
- Medical device makers, water treatment
04 how money comes in
How it earns
- Product sales
Healthcare & Water Technologies: how it makes money
- 2025 net sales $3.23B (+9%), operating EBITDA $972M.
Diversified Industrials
Industrial technologies and building technologies.
01 what it draws on
Inputs & resources
- Polymers and specialty materials
02 what it does
Activities
- Manufacturing
03 who it serves
Customers
- Industrial and construction markets
04 how money comes in
How it earns
- Product sales
Diversified Industrials: how it makes money
- 2025 net sales $3.62B (−3%), operating EBITDA $800M.
Government & regulation around the business
Non-market factors from the company’s filings: what governments and regulators fund, buy, set, approve or restrict, and which part of the flow above each one touches.
DuPont carries PFAS-related indemnities and faces EPA actions.
Environmental rules
PFAS indemnification
Recorded a $185M indemnification liability for its PFAS cost-sharing arrangement at end-2025.
Constrains the businessTouches: ActivitiesSource: Form 10-K (FY2025)
Approvals & licenses
EPA notice
EPA Region 3 issued a Notice to Show Cause to its Spruance site in March 2025.
Constrains the businessTouches: ActivitiesSource: Form 10-K (FY2025)
Revenue by segment (FY2025)
Unit: $M — bar length = revenue, (%) = share of total company revenue, margin = segment profit ÷ segment revenue × 100
Diversified Industrials
3,616 (53%)profit 800 · margin 22.1%
Healthcare & Water Technologies
3,233 (47%)profit 972 · margin 30.1%
Source: Form 10-K (FY2025) — segment results Profit is segment operating EBITDA (non-GAAP).
10
Contract structureSite analysisShow
Short-term or spot sales carry different earnings quality than long-term or auto-renewing contracts — this shows how the company actually contracts with its customers.
11
Alliances & capital tiesSite analysisShow
Equity stakes, joint ventures, and strategic partnerships disclosed across the 10-K, 8-Ks, and proxy statement.
Business partnership
Chemours and Corteva
A 2021 binding MOU shares eligible PFAS costs among DuPont, Corteva and Chemours.
Source: Form 10-K (FY2025)
12
Customers & suppliersSite analysis
Who the company sells to and buys from. Companies rarely name either, so named counterparties come only from the company's own filings and press releases; otherwise this lists the concentration figures the 10-K discloses.
Customers
Healthcare, water, industrial and construction customers.
Named by the company
No customer is named as significant.
Suppliers
Raw material suppliers.
Named by the company
No supplier is named.
13
Competitors & peersSite analysis
Competitors the 10-K names, and the peer group the company itself chose in its proxy statement. Nothing here is this site's own pick.
The 10-K describes competitors generally (multinationals and regional companies) without naming them.
Competitors named in the 10-K
DuPont's 10-K doesn't name competitors.
Peer group the company chose
2025 compensation peer group, from the proxy statement. Peers are companies the board considers comparable — for example when setting executive pay — not necessarily direct competitors.
Revised for the post-separation company: healthcare, multi-industrial, specialty chemical and building products companies at one-third to three times DuPont's size.
- AptarGroupsite ↗
- Fortivesite ↗
- Parker-Hannifinsite ↗
- Avantorsite ↗
- GE HealthCaresite ↗
- Regal Rexnordsite ↗
- Carlisle Companiessite ↗
- Hubbellsite ↗
- Teleflexsite ↗
- Doversite ↗
- Illinois Tool Workssite ↗
- Trane Technologiessite ↗
- Ecolabsite ↗
- ITTsite ↗
- Emersonsite ↗
- Nordsonsite ↗
Company names link to this site’s analysis where one exists; “site ↗” opens the company’s own website.
14
Six years of financialsFrom SEC data
Each chart's axis holds a single unit (never mixing dollars, %, and $/share). The table's per-period header links to the filing the numbers came from.
Revenue over time
Unit: $M
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-17
Profit over time (operating → net)
Unit: $M
- Pretax income
- Net income
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-17
Margins over time
Unit: %
- Operating margin
- Net margin
formulaoperating income ÷ revenue × 100
formulanet income attributable to the company ÷ revenue × 100
Cash flow over time
Unit: $M (below zero = cash went out)
- Operating CF
- Investing CF
- Free CF
formulacash flow from operations − capital expenditures
termsFree cash flow (FCF) · Cash flow from operations (operating CF) · Capital expenditures (capex)
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-17
Financial stability & capital efficiency
Unit: %
- Equity ratio
- ROE
formulatotal equity ÷ total assets × 100 (as reported in the 10-K)
termsStockholders’ equity · Total assets
formulanet income ÷ average equity (beginning + ending, ÷2) × 100 (as reported in the 10-K)
termsNet income (attributable to the company) · Stockholders’ equity
Earnings per share (EPS) and dividend per share
Unit: $
- EPS
- Dividend per share
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-17
| Line item | FY202010-K on EDGAR ↗ | FY202110-K on EDGAR ↗ | FY202210-K on EDGAR ↗ | FY202310-K on EDGAR ↗ | FY202410-K on EDGAR ↗ | FY202510-K on EDGAR ↗ |
|---|---|---|---|---|---|---|
| Income statement ($M) | ||||||
| Revenue | 20,397 | 12,566 | 13,017 | 6,614 | 6,719 | 6,849 |
| Pretax income | -1,259 | 1,444 | 1,448 | -279 | 117 | 200 |
| Net income (attributable) | -2,951 | 6,467 | 5,868 | 423 | 703 | -779 |
| Revenue growthcalc(this year’s revenue − last year’s revenue) ÷ last year’s revenue × 100 | — | -38.4% | 3.6% | -49.2% | 1.6% | 1.9% |
| Net margincalcnet income attributable to the company ÷ revenue × 100 | -14.5% | 51.5% | 45.1% | 6.4% | 10.5% | -11.4% |
| Balance sheet ($M) | ||||||
| Total assets | 70,903 | 45,707 | 41,355 | 38,552 | 36,636 | 21,575 |
| Total equity | 39,070 | 27,050 | 27,017 | 24,725 | 23,793 | 14,103 |
| Interest-bearing debtSum of short- and long-term borrowings, notes/bonds payable | 15,617 | 10,782 | 8,145 | 7,859 | 7,171 | 3,194 |
| Equity ratio | 54.3% | 57.8% | 64.2% | 63.0% | 63.7% | 64.5% |
| ROE | -7.7% | 19.9% | 22.1% | 1.7% | 3.0% | -4.2% |
| Cash flow ($M) | ||||||
| Operating CF | 4,095 | 2,281 | 588 | 845 | 765 | 560 |
| Investing CF | -202 | -2,401 | 8,923 | 481 | -562 | -374 |
| Financing CF | 3,238 | -6,507 | -7,667 | -2,956 | -1,826 | -1,750 |
| Free cash flowcalccash flow from operations − capital expenditures | 2,901 | 1,493 | -74 | 543 | 480 | 227 |
| Cash and equivalents | 2,544 | 1,972 | 3,662 | 2,392 | 1,792 | 715 |
| Per share & other | ||||||
| EPS ($) | -12.03 | 35.67 | 35.25 | 2.82 | 5.04 | -5.58 |
| BVPS ($) | 157.33 | 154.94 | 173.99 | 169.34 | 167.59 | 102.05 |
| Dividend per share ($) | 3.60 | 3.60 | 3.96 | 4.32 | 4.56 | 4.29 |
| Payout ratiocalcdividend per share ÷ diluted EPS × 100 | — | 10.1% | 11.2% | 153.2% | 90.5% | — |
| P/E (x) | — | 2.8 | 2.4 | 34.2 | 19.0 | — |
| P/B (x)calcfiscal year-end closing price ÷ book value per share | 0.57 | 0.65 | 0.50 | 0.57 | 0.57 | 1.18 |
P/B and EV/EBITDA use each period’s period-end (fiscal year-end) figures, not the current share price. Periods below 1x are shown in red. Figures without a "calc" tag are as reported in the Form 10-K (the consolidated financial statements and, for older years, earlier 10-Ks), pulled automatically from SEC EDGAR. Where a later filing restated a prior period, the restated figure is used.
Last 8 quarters
Three-month figures from 10-Q filings. Change is versus the same quarter a year earlier. Newest quarter on top.
| Quarter ended | Revenue | Net income |
|---|---|---|
| 2026-09-30 | $1.87B+4.1% | $123M |
| 2026-06-30 | $1.82B+4.0% | $143M+142.4% |
| 2026-03-31 | $1.68B+4.3% | $161M |
| 2025-12-31 | $1.69B+0.2% | −$126M |
| 2025-09-30 | $1.8B | −$123M |
| 2025-06-30 | $1.75B | $59M |
| 2025-03-31 | $1.61B | −$589M |
| 2024-12-31 | $1.69B | −$117M |
15
Is ROIC above WACC?From SEC data
ROIC (the return on money invested in the business) above WACC (the cost of raising that money) means the company is creating value. WACC is an estimate, so its assumptions can be adjusted below.
Not enough data (operating income, equity, etc.) to compute ROIC/WACC.
16
What the price implies (DCF)From SEC data
A company's value can be written as its free cash flow divided by (cost of capital − perpetual growth). Working that backwards from the market's valuation shows how much growth the share price assumed — compared here with the company's actual past growth.
Growth the price implies (price on 2026-11-04)
9.0%
Perpetual FCF growth: g = r − FCF ÷ EV = 10.0% − 1.0%
Past FCF growth (FY2020–FY2025)
-39.9%
Compound annual rate, 5 years
Past revenue growth (FY2020–FY2025)
-19.6%
Compound annual rate, 5 years
Inputs (FY2025): free cash flow $227M (operating CF − capex); enterprise value $23.43B = market cap $20.95B (latest close, 2026-11-04) + debt $3.19B − cash and short-term investments $715M; r = WACC of 10.0% using this page’s default assumptions (β 1.06, risk-free 5.0%, market premium 5.5%).
Three WACC scenarios
The same calculation under cautious, base and optimistic cost-of-capital assumptions (risk-free rate fixed at the 10-year Treasury yield). Pick one to load it into the sliders below.
Try your own assumptions
V = FCF ÷ (r − g). It starts at the implied growth rate, where the theoretical value equals today’s enterprise value.
Theoretical enterprise value
$22.7B
FCF $227M ÷ (10.0% − 9.0%)
Theoretical ÷ actual enterprise value
0.97x
Below 1x: these assumptions value the business below the market did
How sensitive the answer is
Theoretical ÷ actual enterprise value for each combination of r and g.
| g \ r | 8.0% | 9.0% | 10.0% | 11.0% | 12.0% |
|---|---|---|---|---|---|
| 0% | 0.12x | 0.11x | 0.10x | 0.09x | 0.08x |
| 2% | 0.16x | 0.14x | 0.12x | 0.11x | 0.10x |
| 4% | 0.24x | 0.19x | 0.16x | 0.14x | 0.12x |
| 6% | 0.48x | 0.32x | 0.24x | 0.19x | 0.16x |
| 8% | — | 0.97x | 0.48x | 0.32x | 0.24x |
A simplified model for seeing what the market price assumes, not a forecast or a target price. It treats free cash flow as growing at one constant rate forever; the result swings widely with small changes in r and g, and is undefined when g reaches r. Free cash flow here is operating cash flow minus capex, which is after interest — a full DCF of enterprise value would use cash flow before interest. Market cap uses the latest close (2026-11-04) × shares at fiscal year-end; free cash flow and WACC inputs are from the latest fiscal year.
17
Earnings qualityFrom SEC dataShow
The same reported profit can mean different things depending on whether it's backed by cash, driven by the core business, or the result of a one-off item. Four checks below.
- !
Operating CF ÷ net income: averages 0.88x
Cash coming in trails reported profit. Worth checking for rising receivables/inventory or one-off gains.
- ✓
Accrual ratio (latest): -4.6%
A small share of profit rests on accounting estimates.
- !
Days sales outstanding: 33 → 45 days
Receivables are growing faster than revenue — worth checking for looser collection terms or channel stuffing.
Operating CF vs. net income
Unit: $M — operating CF above net income means profit is backed by cash
- Operating CF
- Net income
formulacash flow from operations ÷ net income attributable to the company
termsCash flow from operations (operating CF) · Net income (attributable to the company)
formula(net income − operating CF) ÷ average total assets × 100
termsNet income (attributable to the company) · Cash flow from operations (operating CF) · Total assets
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-17
Receivables & inventory days
Unit: days — days grow when receivables or inventory build up faster than sales
- Days sales outstanding
- Days inventory outstanding
formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365
formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365
termsInventory · Cost of revenue (COGS)
Worked examples (latest period)
formulacash flow from operations ÷ net income attributable to the company
termsCash flow from operations (operating CF) · Net income (attributable to the company)
formulaoperating income ÷ income before income taxes × 100
termsOperating income · Income before income taxes (pretax income)
formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365
e.g.($789M + $910M) ÷ 2 ÷ $6,849M × 365 = 45 days
formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365
e.g.($1,130M + $1,172M) ÷ 2 ÷ $4,486M × 365 = 94 days
termsInventory · Cost of revenue (COGS)
18
Who holds the sharesFrom SEC dataShow
How much of the stock large institutional investors report owning on SEC Form 13F, how much the directors and executive officers hold (and how much of the vote they control), and roughly how much is left for individual investors. Shown next to beta so the holder mix can be read alongside how much the stock swings.
Institutions, insiders and everyone else, 13F holdings as of 2026-06-30
“Everyone else” is what remains after shares reported on Form 13F and shares held by directors and executive officers: mostly individual investors, plus non-insider families or foundations and smaller or foreign institutions. The figures have different dates and 13F reports count some shares twice — read it as an approximate split.
- Held by 13F filers
- 73.1%
- Directors & officers (shares)
- <1%
- Everyone else (est.)
- 26.9%
- Directors & officers (voting power)
- <1%
- Institutional-ownership rank
- 368 of 416
- Beta (adjusted)
- 1.06
individuals and other non-13F holders
no separate voting figure; shown as shares
1 = most institutional; 88% of covered companies have more
above 1 = swings more than the market
- 98.8M shares reported by 1,072 13F filers ÷ 135.0M shares outstanding on 2026-07-31. Option positions are excluded.
- Directors and executive officers as a group, from the proxy statement’s beneficial-ownership table; includes shares they can acquire within 60 days.
- A large “everyone else” share can still reflect a family, trust or foundation stake held outside the board; check the proxy statement’s 5% holders.
Sources: SEC Form 13F data set (holdings as of 2026-06-30) · Form DEF 14A filed 2026-04-10 (beneficial ownership table) · Form 10-Q cover page (shares outstanding as of 2026-07-31)
19
Strengths & weaknessesSite analysis
Strengths
1. Simpler portfolio
After spinning off Qnity and selling Aramids, DuPont focuses on healthcare, water and industrial businesses.
Evidence: 8-K filed 2025-11-03; Q2 2026 press release
2. Healthcare and water growth
Healthcare & Water net sales rose 9% in 2025 on 7% volume growth.
Evidence: Form 10-K (FY2025)
3. Lower debt
Interest-bearing debt fell to about $3.2B at the end of 2025.
Evidence: SEC EDGAR XBRL
Weaknesses
1. PFAS legacy
DuPont shares PFAS costs; in September 2026 it joined a $455M North Carolina settlement payable over 15 years (shared under the MOU).
Evidence: 8-K filed 2026-09-10
2. Shrinking company
Net sales from continuing operations are about half of the 2022 reported level because of divestitures and spin-offs.
Evidence: SEC EDGAR XBRL
20
What draws investors to itSite analysis
Why the stock can look attractive to investors — each point paired with what has to hold for it to stay true, and the opposing view. This is this site's analysis, not a recommendation to buy or sell.
P/E (FY2025)
—
Price at fiscal year-end ÷ diluted EPS
Dividend yield (FY2025)
3.56%
Dividends per share ÷ fiscal year-end price
Payout ratio (FY2025)
—
Dividends per share ÷ diluted EPS
FCF yield (FY2025)
1.4%
(Operating CF − capex) ÷ market cap
1. Focused growth company
2026 guidance was raised; Q2 organic sales grew 4%.
- What has to hold
- Healthcare and water keep growing.
- The other side
- PFAS liabilities.
Evidence: Q2 2026 press release
2. Capital returns
Dividends plus buybacks.
- What has to hold
- Free cash flow conversion stays high.
- The other side
- Dividend was cut after the Qnity spin (Q4 2025 rate lower).
Evidence: SEC EDGAR XBRL; Q2 2026 press release
2021–2022 figures are as originally reported (including businesses later divested or spun off) and are not comparable with 2023–2025 continuing operations. Per-share figures are adjusted for the June 2026 1-for-3 reverse split. Operating income is not reported. Historical P/E for 2021–2022 looks very low because those years' EPS includes divested businesses and gains, while the price history is adjusted for later spin-offs.
21
ResilienceSite analysisShow
How well the company could absorb a bad year: its financial buffer, how its revenue and profit held up in the worst year on record, and what the 10-K says about the business's exposure to shocks. Figures and filing statements only — no overall rating.
1. Financial buffer (FY2025)
Cash & short-term investments ÷ debt due within a year
11.9x
$715M vs. $60M
Interest coverage (operating income ÷ interest expense)
Not disclosed
The income statement has no operating income line.
Free cash flow ÷ dividends paid
0.4x
$227M vs. $597M (FCF = operating CF − capex)
2. Worst year in the record, and the recovery
| Figure | Worst year-over-year change | Back to the prior level? |
|---|---|---|
| Revenue | -49.2% in FY2023 ($13.02B → $6.61B) | Not yet, as of FY2025 |
Covers only the 6 fiscal years on record (FY2020–FY2025), which may not include a full recession — the worst year here isn’t necessarily how the company would fare in a severe downturn.
3. Business resilience (from the 10-K)
Diversified end markets
Healthcare, water, industrial and building markets.
Source: Form 10-K (FY2025)
Cash proceeds
About $1.2B of cash from the Aramids sale in 2026.
Source: Q2 2026 press release
22
Legal & regulatory mattersSite analysisShow
Lawsuits, government investigations, enforcement actions and settlements the company discloses — where each stands, what is at stake, and what comes next. From the 10-K's Legal Proceedings and contingencies note, the latest 10-Q, and 8-Ks.
DuPont's main legal exposure is legacy PFAS litigation shared with Chemours and Corteva under a cost-sharing MOU. It is named in about 12,400 AFFF personal-injury cases in the federal MDL, mostly on fraudulent-transfer theories, and in state attorney general suits. An $875 million New Jersey settlement awaits final court approval.
2 open matters (1 flagged as major) · 1 settled or closed
AFFF/PFAS multidistrict litigation
PendingEnvironmentalMajorAbout 12,400 personal-injury cases, plus water districts, individuals and state AGs (AFFF MDL, D.S.C.)
Plaintiffs allege contamination and injury from firefighting foam. DuPont never made AFFF and is named mostly on fraudulent-transfer claims tied to the Chemours and DWDP separations. In 2023 the companies settled public water system claims for $1.185 billion, of which DuPont paid about $408 million. Personal-injury claims outside eight specified health conditions face dismissal.
- Next step
- DuPont is in mediation discussions on the personal-injury docket.
Source: Form 10-Q (quarter ended 2026-06-30) — Legal Proceedings
North Carolina and other state AG PFAS suits
PendingEnvironmentalNorth Carolina Attorney General and municipalities; other state AGs
State suits outside the MDL seek natural resource damages, cleanup costs, abatement and punitive damages for non-AFFF PFAS contamination, most with fraudulent-transfer claims.
Source: Form 10-Q (quarter ended 2026-06-30) — Legal Proceedings
State of New Jersey PFAS and legacy sites settlement
SettledEnvironmentalState of New Jersey (D.N.J., Camden); Chemours; Corteva/EIDP
Resolves New Jersey's claims over legacy substances, statewide PFAS (including AFFF) and four historic EIDP sites, with ongoing remediation duties at those sites. Qnity will bear 44% of DuPont's funding obligation.
- Amounts
- $875 million aggregate over 25 years; DuPont's share is recorded at a present value of $188 million.
- Next step
- Final court approval pending after the State's July 6, 2026 filing.
Source: Form 10-Q (quarter ended 2026-06-30) — Legal Proceedings
Based on Form 10-Q (quarter ended 2026-06-30) — Legal Proceedings, reviewed 2026-10-18. Routine ordinary-course claims are not listed. “Major” is this site’s judgment of which matters could materially affect results.
23
Risks (including geopolitical)Site analysis
Starting from the 10-K's Risk Factors section, organized by category — geopolitical, currency, raw materials, regulatory, disaster, and more — with impact and likelihood assessed by this site.
Risk map
Vertical = impact on results, horizontal = likelihood. Upper right = most severe. Numbers match the list below (placement is this site’s own assessment).
Likelihood →
"Company disclosure" vs. "this site’s assessment"
The description and mitigation for each risk are this site’s summary of the 10-K’s "Risk Factors" section. Impact and likelihood are this site’s own assessment, not the company’s — where the company discloses its own likelihood assessment, that is noted in the summary.
Impact is judged from how large the affected business is relative to total revenue/profit, and from the risk’s track record of moving results in the past. Likelihood is judged from the filing’s wording and the current business environment (already occurring, or recurring). See the rating criteria.
- 1Law & regulation
PFAS litigation
- Company disclosure (summarized from the 10-K)
- Pending and future PFAS/PFOA litigation, including personal injury and natural resource damages, plus remediation and regulatory changes.
- Company’s stated mitigation
- Cost-sharing MOU with Chemours and Corteva; settlements.
- This site’s assessment
- Impact High / Likelihood High
- 2M&A & integration
Separation risks
- Company disclosure (summarized from the 10-K)
- Disputes or unanticipated costs related to the Qnity separation.
- Company’s stated mitigation
- Separation agreements with Qnity.
- This site’s assessment
- Impact Med / Likelihood Med
- 3Competition & technology shift
Competition
- Company disclosure (summarized from the 10-K)
- Competitors include multinationals and regional companies; competition is driven by innovation, technology, sustainability and price.
- Company’s stated mitigation
- Proprietary technologies and technical support.
- This site’s assessment
- Impact Med / Likelihood Med
- 4Demand & macro
Construction and industrial demand
- Company disclosure (summarized from the 10-K)
- Diversified Industrials sales fell 3% in 2025.
- Company’s stated mitigation
- Not stated in the filings.
- This site’s assessment
- Impact Med / Likelihood Med
24
What changed in the risk factorsFrom SEC data
Paragraphs in the latest 10-K's Risk Factors that have little overlap with the year before, and paragraphs that were dropped.
New or substantially reworded (8)
Risks Relating to the Qnity Distribution, M&M Divestitures, N&B Transaction, the DWDP Distributions and the Aramids Divestiture
In addition, the Electronics Separation and Distribution Agreement and that certain assignment agreement, effective as of November 1, 2025, between DuPont and Qnity (the “Legacy Liabilities Assignment Agreement”) provide that, among other things, each of DuPont and Qnity are responsible for their respective Applicable Percentage of certain legacy and other liabilities (including Legacy Liabilities (as defined in the Corteva Letter Agreement), funding obligations of DuPont under the MOU, legacy PFAS liabilities and liabilities related to businesses and operations of DuPont that were previously discontinued or divested).
The timing and outcome of the Aramids Divestiture is subject to risk and uncertainties.
The Aramids Divestiture is expected to close around the end of the first quarter 2026, subject to customary closing conditions and receipt of regulatory approvals. Read more
Factors that could affect DuPont’s ability to realize the anticipated benefits from the Aramids Divesture include, but are not limited to: (i) the parties’ ability to meet expectations regarding the timing, completion (if at all), accounting and tax treatment of the proposed transaction, including (x) any failure to obtain necessary regulatory approvals or to satisfy any of the other conditions to the proposed transaction, (y) the possibility that unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies that could impact the value, timing or pursuit of the proposed…
DuPont’s operations require the continued availability of energy and raw materials and rely on third-party suppliers, contract manufacturers and service providers. Read more
The Company’s supply chains are complex and extend across multiple countries in all regions of the world, and, therefore, are subject to global economic and geopolitical dynamics and risks.
The Company’s results are affected by its ability to foresee and respond to competitive conditions and customer preferences.
Risks related to recent trade disputes, responsive actions, investigations by foreign governments, regulations and policies could have an adverse impact on our operations and reduce the competitiveness or availability of our products relative to local and global competitors.
Trade regulations, policies and disputes as well as geopolitical changes and trends such as populism, protectionism and economic nationalism can and have resulted in increased tariffs and trade barriers, which can and have limited DuPont’s ability to sell certain products to certain customers, and have otherwise impacted its global supply and distribution chains and research and development activities. The extent, duration or escalation in specific trade tensions, such as between the U.S. and China, or in the global trade conflict more broadly, could be harmful to global economic growth, increase market uncertainty and volatility and adversely impact the Company’s business in or with China or other countries. The resulting impact on general economic conditions and on DuPont’s business are uncertain and depend on various factors, such as negotiations between the U.S. and affected…
No longer in the text (4)
DuPont may be unable to achieve all the benefits that it expects to achieve from the Intended Electronics Separation, if the Intended Electronics Separation is effected at all.
The success of the Intended Electronics Separation ultimately depends on, among other things, DuPont's ability to internally separate the Electronics business in a manner that facilitates the Intended Electronics Separation on a U.S. Read more
federal income tax-free basis and enables the future Electronics company as well as “new” DuPont, as a diversified industrials-focused company, (the “FutureCos” and each, a “FutureCo”), to benefit from increased focus and agility in their respective industries.
DuPont, and each of its businesses, has and continues to benefit from efficiencies through the optimization of its global footprint, leveraging of corporate, procurement and functional services and costs across all of its businesses. Read more
While the Intended Electronics Separation is expected to create dis-synergies, the intent is to stand the FutureCos in a way that is favorably competitive for each FutureCo’s respective industry.
The separation and distribution transactions necessary to effectuate the Intended Electronics Separation will be complex, costly and time-consuming, and are subject to difficulties, uncertainties and unanticipated risks, each of which may diminish the benefits the Company expects to realize from the Intended Electronics Separation. These include, but are not limited to:
12 more paragraphs differ; the filings below have the full text.
Matched automatically, quoted as filed, and may include rewording of an existing risk. Compares Item 1A of the 10-K filed Feb 17, 2026 ↗ with the 10-K filed Feb 14, 2025 ↗.
25
What to watch going forwardSite analysis
- Organic growth after portfolio changes.
- PFAS settlements.
- Buybacks ($250M planned in Q3 2026).
- Arclin equity stake and note.
26
Source documentsShow
This page's financial figures come from the Form 10-Ks listed below. Check the original filings for full detail.
Last updated
Analysis last edited: November 6, 2026 · Financial data fetched: October 17, 2026 10:21 (SEC EDGAR) · Source 10-K filed: February 17, 2026
Built on10-K FY2025 · filed 2026-02-17
Next update expectedAfter FY2026’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.
This page is this site’s own analysis based on public information, and does not represent DuPont’s views. It is not a recommendation to buy or sell any security, and this site does not guarantee the accuracy of any figure or statement here. Always verify against the original source documents before making an investment decision.